OncologyLung Neoplasms

EGFR-Mutated Lung Cancer: A New Survival Benchmark

Amivantamab plus lazertinib vs osimertinib: a survival benchmark four years in the making

Published 28 July 2026SR-2026-004

EditorMara Voss

CopywritersEditorial Team

Coming Soon

EGFR-Mutated Lung Cancer: A New Survival Benchmark

Amivantamab plus lazertinib vs osimertinib: a survival benchmark four years in the making

Why We Are Covering This

MARIPOSA projects overall survival beyond four years in EGFR-mutated lung cancer for the first time, and the subcutaneous approval in late 2025 makes the combination accessible outside academic centers today.

What to Expect

You will leave knowing how to weigh amivantamab plus lazertinib against osimertinib, what the subcutaneous formulation means for clinic workflow, and which biomarkers predict who benefits most.

Be first when this report publishes

The Life Science Feed briefing covers every major trial readout, approval, and pipeline shift, weekly.

Get the briefing first

thelifesciencefeed.com · Special Report

SR-2026-00407/26

Solid Tumors

Bowhead Whale Longevity Genes Offer Clues for Cancer, Aging

Insights from the bowhead whale's exceptional lifespan and cancer resistance point to novel genetic pathways for human anti-aging and oncology research.

Prostatic Neoplasms

Prostate Care: Balancing Immediate Relief with Long-Term Retreatment

Managing benign prostatic hyperplasia requires weighing rapid symptom improvement against the need for future interventions. Clinicians must consider patient preference and disease progression.

Breast Neoplasms

Genetic Test Identifies Breast Cancer Patients Who May Avoid Chemotherapy

A genetic test can identify patients with early-stage, hormone receptor-positive, HER2-negative breast cancer who may safely forgo adjuvant chemotherapy.

Breast Neoplasms

Giredestrant Improves Breast Cancer Survival Regardless of Menopause

Giredestrant, an oral selective estrogen receptor degrader (SERD), demonstrated improved invasive disease-free survival in early breast cancer.

EGFR-Mutated Lung Cancer: A New Survival Benchmark

EGFR-Mutated Lung Cancer: A New Survival Benchmark

Be first when this report publishes

Related Articles